Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Dosing and administration: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

7 questions · 3 sources

Dosing

What is the Kisqali dose for metastatic breast cancer?

How is the Kisqali dose lowered to manage side effects?

Note: The second passage is the advanced or metastatic breast cancer section of Table 1 of the Prescribing Information; each dose level is followed by its number of 200 mg tablets.

How is the Kisqali dose adjusted for QT prolongation?

How is the Kisqali dose adjusted for elevated liver enzymes?

How is the Kisqali dose adjusted for neutropenia?

Treatment combinations

How are the aromatase inhibitor and fulvestrant given with Kisqali?

Treatment duration

How long do patients take Kisqali for metastatic breast cancer?